Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S38-S46 , April 2003

Possible Role for Memantine in Protecting Retinal Ganglion Cells from Glaucomatous Damage

  • Stuart A Lipton, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint address: Stuart A. Lipton, MD, PhD, Director, Center for Neuroscience and Aging, The Burnham Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA

References 

  1. Ascher P, Marty A, Neild TO. The mode of action of antagonists of the excitatory response to acetylcholine in aplysia neurones. J Physiol (Lond). 1978;278:207–235
  2. Ascher P, Large WA, Rang HP. Studies on the mechanism of action of acetylcholine antagonists on rat parasympathetic ganglion cells. J Physiol (Lond). 1979;295:139–170
  3. Bonfoco E, Krainc D, Ankarcrona M, et al.  Apoptosis and necrosis (two distinct events induced respectively by mild and intense insults with NMDA or nitric oxide/superoxide in cortical cell cultures). Proc Natl Acad Sci USA. 1995;92:7162–7166
  4. Bormann J. Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels. Eur J Pharm. 1989;166:591–592
  5. Budd SL, Tenneti L, Lishnak T, Lipton SA. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proc Natl Acad Sci USA. 2000;97:6161–6166
  6. Brooks DE, Barcia GA, Dreyer EB. Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res. 1997;58:864–867
  7. Carter-Dawson L, Crawford LJ, Harwerth RS. Vitreal glutamate concentration in monkeys with experimental glaucoma. Invest Ophthalmol Vis Sci. 2002;43:2633–2637
  8. Chen H-SV, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells (uncompetitive antagonism). J Physiol (Lond). 1997;499:27–46
  9. Chen H-SV, Pellegrini JW, Aggarwal SK. Open-channel block of NMDA responses by memantine (therapeutic advantage against NMDA receptor-mediated neurotoxicity). J Neurosci. 1992;12:4427–4436
  10. Chen H-SV, Wang YF, Rayudu PV. Neuroprotective concentration of the NMDA open-channel blocker memantine are effective without cytoplasmic vacuolization following post-ischemic administration and do not block maze learning or LTP. Neuroscience. 1998;86:1121–1132
  11. Choi Y-B, Tenneti L, Le DA. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nature Neurosci. 2000;3:15–21
  12. Dawson VL, Dawson TM, Bartley DA. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993;13:2651–2661
  13. Dawson VL, Dawson TM, London ED. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA. 1991;88:6368–6371
  14. Dreyer EB, Grosskreutz CL. Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Clinical Neuroscience. 1997;4:270–273
  15. Dreyer EB, Lipton SA. New perspectives on glaucoma. JAMA. 1999;281:306–308
  16. Dreyer EB, Zhang D, Lipton SA. Transcriptional or translational inhibition blocks low dose NMDA-mediated cell death. NeuroReport. 1995;6:942–944
  17. Dreyer EB, Zurakowski D, Schumer RA. Elevated glutamate in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299–305
  18. Franco-Bourland RE, Guizar-Sahagun G, Garcia GA. Retinal vulnerability to glutamate excitotoxicity in canine glaucoma (induction of neuronal nitric oxide synthase in retinal ganglion cells). Proc West Pharmacol Soc. 1998;41:201–204
  19. Gu Z, Yamamoto T, Kawase C. Neuroprotective effect of N-methyl-d-aspartate receptor antagonists in an experimental glaucoma model in the rat. Nippon Ganka Gakkai Zasshi. 2000;104:11–16
  20. Hare W, WoldeMussie E, Lai R. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol. 2001;45(Suppl 3):S284–S289
  21. Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol. 1998;18:485–492
  22. Johnson J, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987;325:529–531
  23. Koroshetz WJ, Moskowitz MA. Emerging treatments for stroke in humans. Trends Pharmacol Sci. 1996;17:227–233
  24. Le DA, Lipton SA. Potential and current use of N-methyl-d-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging. 2001;18:717–724
  25. Lipton SA. Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology. 1992;42:1403–1405
  26. Lipton SA. Prospects for clinically-tolerated NMDA antagonists (open-channel blockers and alternative redox states of nitric oxide). Trends Neurosci. 1993;16:527–532
  27. Lipton SA. Molecular mechanisms of trauma-induced neuronal degeneration. Curr Opin Neurol Neurosurg. 1993;6:588–596
  28. Lipton SA, Choi Y-B, Pan Z-H. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 1993;364:626–632
  29. Lipton SA, Choi Y-B, Takahashi T. Cysteine regulation of protein function—as exemplified by NMDA-receptor modulation. Trends Neurosci. 2002;25:474–490
  30. Lipton SA, Rayudu PV, Choi Y-B. Redox modulation of the NMDA receptor by NO-related species. Prog Brain Res. 1998;118:73–82
  31. Lipton SA, Rosenberg RA. Mechanisms of disease (Excitatory amino acids as a final common pathway in neurologic disorders). N Engl J Med. 1994;330:613–622
  32. Lipton SA, Wang YF. NO-related species can protect from focal cerebral ischemia/reperfusion. In:  Krieglstein J,  Oberpichler-Schwenk H editor. Pharmacology of Cerebral Ischemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 1996;p. 183–191
  33. Lucas DR, Newhouse JP. The toxic effect of sodium l-glutamate on the inner layers of the retina. Am Med Assoc Arch Ophthalmol. 1957;58:193–201
  34. Lutsep HL, Clark WM. Neuroprotection in acute ischaemic stroke. Current status and future potential. Drug R and D. 1999;1:3–8
  35. Naskar R, Vorwerk CK, Dreyer EB. Saving the nerve from glaucoma (memantine to caspases). Semin Ophthalmol. 1999;4:152–158
  36. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115:497–503
  37. Okamoto S-I, Li Z, Ju C, Schölzke MN. Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. Proc Natl Acad Sci USA. 2002;99:3974–3979
  38. Olney JW, Ho OL. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature. 1970;227:609–611
  39. Olney JW. Glutamate-induced retinal degeneration in neonatal mice (electron microscopy of the acutely evolving lesion). J Neuropathol Exp Neurol. 1969;28:455–474
  40. Orgogozo JM, Rigaud AS, Stoffler A. Efficacy and safety of memantine in patients with mild to moderate vascular dementia (a randomized, placebo-controlled trial (MMM 300)). Stroke. 2002;33:1834–1839
  41. Osborne NN. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis Neurosci. 1999;16:45–52
  42. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targ. 2001;2:241–271
  43. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacology. 1999;38:735–767
  44. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents NMDA receptor-mediated neurotoxicity. Ann Neurol. 1993;33:403–407
  45. Quigley HA, Nickells RW, Kerrigan LA. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774–786
  46. Rang HP. Drugs and ionic channels (mechanisms and implications). Postgrad Med J. 1981;57(Suppl 1):89–97
  47. Rogawski MA. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents—toward an understanding of their favorable tolerability. Amino Acids. 2000;19:133–149
  48. Seir el Nasr M, Peruche B, Rossberg C . Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol. 1990;185:19–24
  49. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 1997;37:3483–3493
  50. Tenneti L, DEmilia DM, Troy CM, Lipton SA. Role of caspases in N-methyl-d-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem. 1998;71:946–959
  51. Tenneti L, Lipton SA. Involvement of activated caspase-3-like proteases in N-methyl-d-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem. 2000;74:134–142
  52. Vorwerk CK, Lipton SA, Zurakowski D. Chronic low dose glutamate is toxic to retinal ganglion cells (toxicity blocked by memantine). Invest Ophthalmol Vis Sci. 1996;37:1618–1624
  53. Winblad B, Poritis N. Memantine in severe dementia (results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)). Int J Geriat Psych. 1999;14:135–146
  54. WoldeMussie E, Yoles E, Schwarts M: Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma (in press)
  55. Yun HY, Gonzalez-Zulueta M, Dawson VL. Nitric oxide mediates N-methyl-d-aspartate receptor-induced activation of p21ras. Proc Natl Acad Sci USA. 1998;95:5773–5778
  56. Zeevalk GD, Nicklas WJ. Evidence that the loss of the voltage-dependent Mg2+ block of the N-methyl-d-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J Neurochem. 1992;59:1211–1220
  57. Zurakowski D, Vorerk CK, Gorla M. Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors. Vision Res. 1998;38:1489–1494

PII: S0039-6257(03)00008-0

doi: 10.1016/S0039-6257(03)00008-0

Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S38-S46 , April 2003

Article Tools

* Image Usage & Resolution